No ano passado, Sinovac Biotech Ltd gerou US$ 149.22M em seu segmento de melhor desempenho, Enterovirus 71 vaccines. A região Mainland China teve a maior contribuição, com US$ 261.18M no período.

Por Empresa

Receita

Proporção

Anual

Anual

Trimestral

Enterovirus 71 vaccines

Inactivated hepatitis vaccines

Mumps vaccines

Influenza vaccines

H5N1 vaccines

Other

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Enterovirus 71 vaccines

149.22M(60.65%)

162.54M(70.78%)

121.28M(69.57%)

35.14M(48.52%)

--(--)

Inactivated hepatitis vaccines

57.95M(23.55%)

63.43M(27.62%)

37.85M(21.71%)

20.60M(28.44%)

49.42M(73.30%)

48.45M(76.99%)

47.20M(65.76%)

39.95M(81.18%)

26.94M(47.39%)

Mumps vaccines

19.73M(8.02%)

1.66M(0.72%)

1.67M(0.96%)

477.00K(0.66%)

1.47M(2.18%)

2.15M(3.42%)

1.68M(2.34%)

--(--)

Influenza vaccines

19.14M(7.78%)

2.03M(0.88%)

13.54M(7.77%)

9.83M(13.57%)

12.67M(18.80%)

12.13M(19.28%)

12.16M(16.94%)

9.19M(18.68%)

29.90M(52.61%)

H5N1 vaccines

--(--)

6.39M(8.82%)

3.85M(5.71%)

201.00K(0.32%)

10.74M(14.96%)

--(--)

Other

--(--)

73.41K(0.15%)

--(--)

Por Região

Receita

Proporção

Anual

Anual

Trimestral

Mainland China

Foreign countries

Hong Kong

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Mainland China

261.18M(67.66%)

297.00M(82.19%)

402.96M(85.70%)

1.07B(72.94%)

10.90B(56.28%)

365.62M(71.60%)

227.11M(92.30%)

215.12M(93.67%)

172.90M(99.17%)

71.18M(98.28%)

66.78M(99.06%)

61.95M(98.45%)

70.65M(98.43%)

48.20M(97.93%)

56.41M(99.24%)

Foreign countries

124.83M(32.34%)

64.37M(17.81%)

67.21M(14.30%)

398.74M(27.06%)

8.47B(43.72%)

145.00M(28.40%)

18.94M(7.70%)

14.53M(6.33%)

1.45M(0.83%)

--(--)

Hong Kong

--(--)

1.25M(1.72%)

635.00K(0.94%)

977.00K(1.55%)

1.13M(1.57%)

1.02M(2.07%)

434.76K(0.76%)